Health Articles

Adn ppt canada 20160721 v fm.ppt

Corporate
Presentation
July 15, 2016

Forward Looking Statements
This presentation is not intended as a solicitation or offering of securities in any jurisdiction and the information contained herein in no
way should be construed or interpreted as such. No securities commission or other regulatory authority in Canada or any other
country or jurisdiction has in any way passed upon this information and no representation or warranty is made by VFP Therapies Inc.
and or Red Ore Gold Inc. (the "Company") to that effect.
Cautionary Note Regarding Forward-Looking Statements
This presentation includes and is based in part upon forward-looking statements and forward-looking information (col ectively, "forward-looking statements") within the meaning of applicable Canadian and US securities legislation. All statements included herein, other than statements of historical fact, including, without limitation, plans for and intentions with respect to the company's capitalization, preparation of technical reports, patents, research and development programmes, budgets, projected expenditures, and other milestones, are forward-looking statements. AD NEUROPHARMA Inc. (the "Company") believes that such statements are reasonable, it can give no assurance that such expectations wil prove to be correct. Forward-looking statements are typical y, but not always, identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ material y from those in forward looking statements as a result of various factors, including, but not limited to, the Company's ability to advance its various projects, variations in the nature, quality and quantity of any research drugs the Company may produce or plan to produce, the Company's inability to obtain any necessary permits, consents or authorizations required for its activities, the Company's inability to produce royalties or income successful y or profitably, to continue its projected growth, to raise the necessary capital or to be ful y able to implement its business strategies, regulatory restrictions, defective title to patents, and other risks and uncertainties. There can be no assurance that such forward-looking statements wil prove to be accurate, and actual results and future events could differ material y from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to reissue or update any forward-looking statements as a result of new information or events after the date hereof except as may be required by law. All forward-looking statements and information herein are qualified by this cautionary statement. RD – 2016 – 5

VFP Therapies is a Drug Discovery Pharmaceutical Company, based in Rouen,
France, dedicated to the design of safe and innovative Brain targetting molecules for a
variety of BRAIN DISEASES, especial y Alzheimer's Disease.
VFP has agreed to become a subsidiary of Red Ore Gold Inc., a Canadian reporting
issuer under the name AD NEUROPHARMA INC. (AD.N) and to be listed on a Canadian
stock exchange.
RD – 2016 – 5

Who We Are
• Our Experience Comes From Various Backgrounds
– Chemistry/Biology/Pharmacology R&D plus technology transfer to the private sector • The French Advantage
– France has a much larger pharma industry than Canada Rouen is the key centre of chemistry in France • A New Way of Delivering Drugs to Brain: Brain Targetting
Symptomatic
– Our innovative technology allows us to selectively, and efficiently deliver drugs through the Blood-Brain-Barrier Proof of concept is demonstrated in the field of Alzheimer's Disease for symptomatic therapies (Aricept and Excelon annalogues) – Our technology is a promising and innovative strategy for the brain targeting of butyrylcholinesterase inhibitors. Curative our bioprecursor technology
is a promising and innovative strategy for the brain targeting of acetylcholinesterase inhibitors. May be an effective way to target brain kinases to avoid the formation of neurofibril ary tangles (AD) or to propose new brain tumor treatment. FM – 2016 – 2 AD and Our Bioprecursor
• There is currently no available cure for AD, only symptomatic relief. • Drugs currently in use have serious side effects, and massive side effects at high dosages. • Our Bioprecursor molecule may present a new, safe way to mimick the current AD drugs, such as Aricept or Exilon. • Same biological target (an enzyme cal ed acetylcholine esterase). • Similar and original chemical structures under a special y modifi ed chemical structure which al ows the Bioprecursor to avoid (or to lower) undesired side-effects. • The Bioprecursor is an inactive form which is not (or little) recognized by the biological receptors outside the brain. VFP's Bioprecursor is able to cross the BBB before transforming into the active form which then induces the desired biological effects. • Our Bioprecursor should be able to deliver symptomatic relief for a far longer period, and at far higher dosage, due to our potential ability to aliviate symptoms without the serious and debilitating side effects of current drugs extent. • Our animal testing has demonstrated a significant reduction in side effects such as drooling and shivering. Clinical development studies should normal y confirm that our molecules are less toxic and more effective. FM – 2016 – 2 The Mission
• The bioprecursors VFP has developed (2 current patents) wil be considered as drugs de novo and not as new delivery systems. • As the bioactive forms are mimicking commercial y wel known drugs (Aricept / Esai-Pfizer and Exelon / Novartis) with similar biological targets, we wil take advantage of known animal models for the first phases and clinical development programs for the clinical phases. • Our ambition is to push at least one drug candidate into Phase 1 within 6 months and to complete Phase 1 within 12-18 months. • Such a record, if positive, wil al ow VFP to enter into discussion with pharmaceutical companies either to license our families of products or to negotiate a co-development program for their own drugs (AD or other CNS disease). • With the benefit of over ten years of research by VFP scientists, the VFP approach brings an innovative response to minimizing the noxious side-effects of drugs as wel as overcoming crossing the Blood-Brain-Barrier issue. The completed R & D studies have already demonstrated the technical proof of its concept in initial in vitro and in vivo models. FM – 2016 – 2 Our Know-How
Brain Targeting Drugs
Double Technology Platform: Bioprecursor + Carrier

VFP Therapies Innovative Concept of « Bioprecursor »
No biological activity outside the brain Selective activity inside the brain VFP Therapies Carrier Technology
Specific carriers fitted to drug and brain target Drug bioavailability enhancement Selective release inside the brain
Both Technologies can be applied
to most Drugs for Brain Diseases
FM – 2016 – 2 Our Know-How
Brain Targeting Bioprecursors
VFP Therapies Innovative Concept of « Bioprecursor »
No recognition by the biological receptors Lipophilic molecule crossing the BBB Bioprecursor Activated inside the Brain
Recognition by the biological receptors Induction of the targeted pharmacological effects Limitation of peripheral side-effects
Proof of Concept is Achieved
Successful design of new analog drugs for AD Bioprecursor technology can be applied to other brain diseases FM – 2016 – 2 Our Know-How
The Bioprecursor Concept
How to Design a Bioprecursor?
Biological Target: Acetylcholinesterase
Drug Target: Rivastigmine (Exelon®) Substitutes
FM – 2016 – 2 Our Know-How
The Bioprecursor Concept
How to Design a Bioprecursor?
Biological Target: Acetylcholinesterase
Drug Target: Rivastigmine (Exelon®) Substitutes
FM – 2016 – 2 Proof of Concept
Rivastigmine Substitutes
Biological Trials Are Successful
• First Bioprecursor Gous1 reaches the brain and is activated into API • Improvment of the targeted enzyme inhibition = > 10 times lower isoactive dosis • No long lasting peripheral side-effects in shivering and salivation • The objective of Phase 1 is to demonstrate in humans that Gous1 does not cause the usual side effects currently extent, such as nausia, diarrhoea, insomnia, slowing of the heart beat and eventual blockage, bladder outflow obstruction, chronic pulminary disease, or GI bleeding. Shivering (Central effect)
Salivation (Peripheral effect)
Period (min)
Period (min)
Gous 1 (3 mg/kg) Reference (30 mg/kg) FM – 2016 – 2 Results are patented: PCT Int. Appl., WO 2006/03120 R&D Progress
Rivastigmine Substitutes
• Chemical optimization achieved: 3 Leads identified
– In vitro selection and physicochemical optimization – Successful Enzymatic screening (by blocking the digestive / degredation of the neurotransmitter Aceylcholine one increases the Aceytylcholine level) • Patent WO2006/103120: fully acquired in July 2014
• Current trials
– Successful toxicokinetics studies – Genotoxicity ongoing – End of PoC (PK, BBB crossing study, animal efficiency…) End 2016
– Preclinical trials 2016-2017
– Clinical trials – Phase 1 2017-2018
FM – 2016 – 2 R&D Progress
Donepezil Substitutes
• Same process applied to other AD drugs: Donepezil (Aricept®)
• Patent EP13305088 and PCT 25/01/2014
VFP Therapies owns 70% Exclusive licence Immediate cal optionon the balance of 30% (prizing) • Chemical Optimization: first lead identification
• Next Biological Trials
– Genotoxicity ongoing – Enzymatic screening (several lines) – Toxicokinetics studies FM – 2016 – 2 R&D Progress
PreClinical Status 1
• Note that the development of a drug is never a straight line from the early discovery to the clinical phases and therefore it is better to speak of drug candidates. • 1) Done: selection of some hits/ active molecules on the targetted biological receptor by using in vitro trials. • 2) Done: proof of concept which implies proof that such hits are active on animals by any administrative way (Irwing test). • 3) Done: selection of some lead molecules through supplementary trials: Physicochemical optimisation: solubility, stability. Biological screening in order to avoid undesirable biological effects: genotoxicity, enzymatic screening • This risk of failure has been anticipated by preparing backup molecules during point 3. • 4) Underway, Preclinical Assays: the selected leads molecules (possible drug candidates) wil be subjected to preclinical studies, which take place just before clinical trials (the testing phase in humans).The main goals of pre-clinical studies are to determine the safe dose for first-in-human studies and assess the product's safety profile. FM – 2016 – 2 R&D Progress
Phase 1 & 2
• Achieved: point 1 and 2 which al owed VFP to describe and patent the original molecules (patent n°1) and to achieve part of the proof of concept. As expected, the drug candidates induce low peripheral undesired side-effects and are able to reach the brain where they are in situ biological y activated to induce the targetted biological effect. This has been done on mice and proved that the original concept was good. • VFP has already anticipated some preclinical studies (pharmacokinetic and toxicology) in order to understand the evolution of its molecules in vivo (mice and rats). This al owed VFP to confirm/prove that the bioprecursor reaches the brain very quickly where it is transformed into the active form. Elimination of the resulting metabolites has also been observed. • The first set of drug candidates has been modified due to genotoxic effects (difficult to understand and to anticipate) and VFP has now in hand a new group of molecules belonging to the same original patented family which are selectively active (low activity of the bioprecursor and good activity of the active form), not genotoxic, stable, and soluble. • As these candidates belong to the same family, it is likely that they wil have a similar in vivo behavior and that's what VFP wil have to demonstrate next. FM – 2016 – 2 R&D Progress
PreClinical Status 2
Next: Exploratory Studies as Phase 1 and Phase 2 Studies:
• Similarity between the AD.N bioprecursors and the commercial anti-AD drugs: the
organization of the biological trials organization (preclinical and clinical) of the VFP drug candidates are and wil be designed by a simple analogy with the current anti-AD drugs (rivastigmine and donepezil) which have the same biological target and the same biological behavior. This wil be very helpful during the preclinical phase to prove the efficacity of the VFP bioprecursor. • Phase 1 (usually 10-15 patients/study): the first-in-human trials are usual y performed in
healthy volunteers (but for some conditions, it can also be some patients). First doses of the study drug or treatment are given to a smal number of subjects to gather preliminary data on the pharmacodynamics (what the drug does to the body), the pharmacokinetics (what the body does to the drugs), and the safety (determine safe dosage ranges, to identify side effects). • Phase 2 (usually 20 to 80 patients/study): in this study phase, one is looking for the most
interesting dose of the drug. Basical y, the maximum of expected clinical effect with acceptable side effects. Also referred to as "dose finding". FM – 2016 – 2 Our Know-How
Carriers Technology
• Current specific Carriers targeting Brain Pharmaceuticals
– Modifying BBB Crossing, Stability, Toxicity, Solubility… – API = Drug = smal molecules, peptides… Experience* : GABA, octadecapeptide, galantamine… • Current R&D: inhibitors of kinases, 5-HT4 …
• Other carriers are less efficient or cumbersome to use
FM – 2016 – 2 * Org. Biomol. Chem 2006, 4, 817-825 and 2009, 7, 3666-3673 Original and Unique Technology
Platform for Early Partnership
• AD.N believes that most AD studies in the past have failed due to inadequate funding through out the research and development phase, as the large sample required for testing, due to the nature of the disease, has a high rate of individual drop out, which can significantly affect the research results. • Therefore AD.N wil target a possible immediate partnership with a Pharmaceutical Industry Target to facilitate further research on our drug discovery and brain targeting technologies, over a much longer period post Phase 1. • Strong possibility for a co-development Platform: Bioprecursor or Carrier Technology – New Drugs for Brain Diseases – Life cycle management of commercial drugs – Optimization of molecules under development Tolerance (side-effects) Bioavailabilty, Solubility… – Liberi Life Sciences: it is mandatory for Dutch companies to find industrial partners FM – 2016 – 2 Our Strong Competitive Edge
• Some technologies* are currently available to target drugs to the brain:
– Invasive strategies (BBB disruption, implants…): brain vulnerability
– Non invasive strategies: biological, col oïdal and chemical transport – Biological transport (antibody, chimeric peptides): expensive
– Col oïdal systems (liposomes, nanoparticles): poor selectivity
– Chemical systems (classical prodrugs): poor selectivity
• VFP Therapies Carriers lead to highly improved prodrugs
• VFP Therapies Bioprecursors are innovative and safer prodrugs
The VFP Therapies approach & unique know-how
are a true technological breakthrough
FM – 2016 – 2 * Angew. Chem. Int. Ed. 2011, 50, 7998-8014 Our Company – Current Projects
• Improving our current Pipeline: 2 Patents
AD.N has the ambition to push at least one drug candidate up to the end of clinical phase 1 even to enter into phase 2a by 2018 • Carrying on the exploration of new AD tracks
Alzheimer's treatment
Biological targets
Actions
– Symptomatic Butyrylcholinesterase Deal with University of Caen • Initiating partnerships to fight against other CNS diseases
The AD.N drug delivery experience recently gained on kinases could be valuated to target other brain diseases always difficult to treat like brain tumors (glioblastoms). Such a development wil be organized in the frame of partnerships with pharmaceutic companies to search the best synergy between drud discovery and drug delivery. FM – 2016 – 2 Our Company – Current Projects
New AD approaches already studied by AD.N
• Butyrylcholinesterase inhibitors: butyrylcholinesterase is another biological target for a new
symptomatic treatment of AD but this enzyme cannot be targetted by the existing drugs without inducing undesirable side-effects as it is mainly present outside the brain. So the AD.N bioprecursor technology is a promising and innovative strategy for the brain targeting of butyrylcholinesterase inhibitors. • α-Secretase inhibitors: the formation of amyloïd plaques is due to accumulation of the β-amyloïd
peptide resulting from the bad activity ratio between 2 enzymes, α- vs β-secretases. Activation of the good α-secretase has been proven to be an interesting target but developments by other research teams had to be stopped, due to deleterous side-effects as this enzyme is also present outside the brain, and particularly in the heart. So the AD.N bioprecursor technology is a promising and innovative strategy for the brain targeting of α-secretase inhibitors. • Kinases inhibitors: Besides the formation of β-amyloid plaques, the abnormal accumulation of Tau
protein and the formation of neurofibril ary tangles are also implicated in the progression of AD. The hyperphosphorylation of Tau by some overexpressed kinases such as DYRK1a or GSK3b has been postulated to be a major contributor to this phenomenom causing neural apoptosis. This is why these enzymes are promising therapeutic targets for the development of a curative therapy for AD using AD.N's know how. FM – 2016 – 27 Current Use of Proceeds Targets
• Funding the projects
*to be matched 1/1 by the Region of Normandy
• Improving an efficient research tool and Strengthening our strong R&D Team
– Experienced management Core Team ready to start – Research Centre 2016-2017: 200 m² – Our own research center 2018-2019: 800 m2 FM – 2016 – 2 Our Company – Pipeline Development
Patent  1  &  2
Proof  of  concept  on  animals
Phase  I  trials
Patent  1
Proof  of  concept  on  animals
AChE  &  BuChE  inhibitors
Phase  I  trials
Proof  of  concept  on  animals
inhibitors  -­‐  5-­‐HT4  &  5-­‐HT6 Disease
Phase  I  trials
FM – 2016 – 2 Our Company – R&D Costs Plan
R & D Expenses
/ 5 research axis:
4 lead bioprecursors developed until Animal PoC 2 lead bioprecursors developed until preclinical phase 1 lead bioprecursor
developed until end
of Phase I  
FM – 2016 – 2 Our Company – Exit Strategy
• Return on Investment:
– By 2018: One lead molecule ending phase 1 and entering phase 2a
– 2018: negotiation of a 1st licence with a Big Pharma
– 2018-2019: € 20-30 M (cumulative upfront payments)
– 2019-2024: € 80-100 M (cumulative milestones payments)
– 2025-2034: € 4.6 B (royalties)
• Market's Benchmark (achievement of the defined key corporate goals)
Enhanced Value of VFP Therapies above € 200 M € by 2019-2020.
FM – 2016 – 2 Our Company – Assets
VFP is a private company registered in France (August 2012)
3 years R&D experience + strong IP strategy based on 12 years of development  
President – Pr. Francis Marsais 2014: 5 Employees (PhDs and Technicians) CSO – Dr. Vincent Gembus 2016: 10 Employees apart from the office staff 2014: Independant Lab (100 m²) – Lease with the University of Rouen 2018: Own Research Centre (800-1000 m²) 2 Patents filed by public organization • WO2006/103120: VFP Therapies owner • EP 13305088 (PCT 01/2014): VFP Therapies co-owner (70%) FM – 2016 – 2 Our Company – Future Organization* Chart
The Board
Robin DOW HBA, MBA, FCSI (Vancouver, BC), Chairman & Director
Mr. Dow has forty years experience in organizing, funding, and successful y obtaining public listing for start up operations . Francis MARSAIS (Rouen, France) President & CEO, Director
PhD in Organic Chemistry – 40 years experience in chemistry…15 years' experience in chemical R&D and industrial project management. Fabrice HEITZMANN (Rouen, France) Resources Management, Director
PhD in Life Sciences (Oncology) - Purchasing manager at Fournier Laboratories then Sanofi-Aventis. Vice-president of Clemann Group since 2012 (advising biotechs). Dr. Patrick BARNABE M.D. (Ottawa, ON), Director
Medical Doctor whose financial activities focus on promoting technological transfer between various Canadian, American, Japanese and European private and public companies. In 2000, Dr. Barnabe co-founded, with Professor Arel a, Perigene Inc., a scientific intel ectual property trust. Perigene now owns platform technologies in the fields of chemistry, organic chemistry and Immunology. Kristine DORWARD MBA, BSc, CLP. (Montreal, QC), Director
More than 18 years in the pharmaceutical and biotech industry, involving senior leadership positions in licensing,
acquisitions, marketing and business development encompassing global markets. Kristine has completed numerous
due diligence evaluations as part of pipeline planning and acquisitions to drive corporate growth. Recent board
and audit committee experience with a publicly-listed medical device company.

FM – 2016 – 2 Our Company – Future Organization* Chart
The Research Team – Rouen, France
Francis Marsais and Fabrice Heitzmann
Vincent GEMBUS Scientific Management
PhD in Organic Chemistry – 10+ years experience in chemistry and medicinal chemistry. Strong experience in pharmaceutical development since 2006. Patrice BINAY Manufacturing and Control
PhD in Organic Chemistry – 20+ years experience in pharmaceutical industry. Strong experience in formulation, quality management and CMOs relationships. Christophe CLEMENT Global Development
MsC in Biochemistry – 15 years experience in biological studies and medical affairs. President of Clemann Group since 2012 (advising biotechs). Hélène TEMMEM Business Development
Diploma in Pharmacy and in Political Sciences – 20+ years experience in pharmaceutical industry. Business development & IP management at Roussel Uclaf then in/out licensing at Sanofi-Aventis. Nigel ROOME Pathology & Toxicology
PhD in Experimental Pathology – 30+ years experience in pharmaceutical industry. Former Global scientific advisor and Preclinical safety co-ordinator at Sanofi-Aventis. FM – 2016 – 2 Our Company – Future Organization* Chart
Scientific Advisory Committee
Pascal GEORGE (Rouen, France), Pharmacology
PhD in Organic Chemistry – 10+ years experience at Sanofi-Aventis as Head of the CNS research department. Former President of the French Society for Therapeutic Chemistry. J. David MASON M.Eng, B.A.Sc. (Toronto, ON)
Specialist in financial markets and emerging company development. Raised over $500 Mil ion of startup capital in past several decades for over 250 companies. Marco PETRELLA MSc, PhD (Montreal, QC), Drug Development and Medical Sciences Consultant
During the course of the past 30 years, Dr. Petrel a has occupied key positions in Clinical and Product Development, Commercial Strategy, and most recently, Medical Affairs with a wide array of pharmaceutical and biotechnology companies. He possesses considerable therapeutic expertise in oncology/hematology, liver diseases, and in particular, with HIV/AIDS and viral hepatitis. FM – 2016 – 2 Capital Structure
Shares issued and O/S post Consolidation*: 11,084,267
New Issue (max)@ $1 Unit**: 3,000,000
14,084,267
% owned of ADN by new money: * On or about September 2nd, 2016, at a shareholders' meeting, Red Ore Gold Inc. wil
consolidate it's shares one new for 30 old and change its name to AD Neuropharma, prior to the share exchange with VFP. ** Each Unit consists of one common share and one warrant @ $1.25 /2 yrs.
Minimum 1,000,000Uunits, Maximum 3,000,000 Units. Trading on a Canadian stock exchange expected Q3 2016. FM – 2016 – 2 Our Company – Environment
Financial support: 875 k€ over 4 years (+ CIR 380 k€)
Scientific support
Technological support
FM – 2016 – 2 For further information please contact:
Francis Marsais, President & CEO
+ (33) 680 325 764 [email protected]
Robin Dow, Chairman
+(1) 604 355 9986 [email protected]

Source: http://adneuro.ca/assets/adn.ppt.pdf